Sean Cushman, OD
Optometrist · Salt Lake City, UTNPI 1023686474
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,225 of the $24,862 with a category attached, or 69.3%. Bausch & Lomb Americas Inc. accounts for 91.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $22,715, more than ten times the $265 reported in 2022. Among optometrist clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $175.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$23K
- Biotissue Holdings Inc.$705
- Sun Pharmaceutical Industries Inc.$350
- Tarsus Pharmaceuticals, Inc.$280
- Oyster Point Pharma, Inc.$258
- Alcon$142
- plus $412 from 7 others
What the payments were for
- Speaking & faculty fees$17,22569%
- Travel & lodging$3,45714%
- Food & beverage$4,18017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 94 | $22,715 |
| Biotissue Holdings Inc. | 12 | $705 |
| Sun Pharmaceutical Industries Inc. | 4 | $350 |
| Tarsus Pharmaceuticals, Inc. | 7 | $280 |
| Oyster Point Pharma, Inc. | 4 | $258 |
| Alcon | 6 | $142 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| AbbVie | 5 | $119 |
| Dompe US, Inc. | 5 | $99 |
| Kedrion Biopharma, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Thea Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,862 in reported general payments places this provider in the 95th percentile of 423 optometrist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 55 | $54,273 |
| XiidraLifitegrast | 39 | $46,640 |
| XdemvyLotilaner | 12 | $23,434 |
| MieboPerfluorohexyloctane/Pf | 29 | $21,548 |
| TyrvayaVarenicline Tartrate | 13 | $9,533 |
| LumiganBimatoprost | 19 | $8,304 |
| Cyclosporine | 14 | $5,212 |
| Fluorometholone | 55 | $4,182 |
| Prednisolone Acetate | 55 | $2,273 |
| Loteprednol Etabonate | 11 | $2,159 |
| Latanoprost | 190 | $1,794 |
| ValacyclovirValacyclovir Hcl | 25 | $1,495 |
| Doxycycline Monohydrate | 21 | $1,191 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $568 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $22,715 | $68,18868 claims |
| AbbVieRestasis, Lumigan | $119 | $62,57774 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $280 | $23,43412 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $258 | $9,53313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 optometrist providers in Utah.
Other optometrist in Salt Lake City
- Camron BatemanSalt Lake City$10K
- Karri BureshSalt Lake City$9K
- Kaeleen FransonSalt Lake City$8K
- Leidy Dayan Monsalve-WardSalt Lake City$5K
- Rick RobisonSalt Lake City$4K
- Jeffrey SimmonsSalt Lake City$4K
- Ryan GarberSalt Lake City$4K
- Christopher ValliereSalt Lake City$3K
- Stephen ReinhartHill Afb$134K
- Robert WooldridgeMurray$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.